Omeros announces enrollment in phase 1 clinical trial evaluating OMS824 (Omeros) - Nov 1, 2012 - Omeros has enrolled the first subject in P1 clinical trial for OMS824; Data is expected before year end
Anticipated P1 data • Trial initiation date • Schizophrenia
|
|
Omeros Corporation (NASDAQ: OMER) today announced that the first subject has been enrolled in the Company's Phase 1 clinical trial evaluating OMS824, the lead compound in Omeros' phosphodiesterase 10 (PDE10) program. OMS824 selectively inhibits PDE10, an enzyme expressed in areas of the brain linked to a wide range of diseases that affect cognition, including schizophrenia and Huntington's disease. This Phase 1 dose-ranging study is evaluating the drug's safety, tolerability and pharmacokinetics in healthy subjects, and Omeros expects clinical data before year end...
|